Michael Sitzman joined McDermott Will & Emery as a partner in its intellectual property practice group in San Francisco, the firm announced Tuesday.
Sitzman represents biotechnology and brand-side pharmaceutical companies in high-stakes biologic and drug patent litigation, the firm said.
He has litigated cases involving recombinant DNA, chimeric antigen receptor technology, glycobiology, small molecule drugs, antisense technology, protein synthesis and regulation, and immunological markers.
This story was produced by Bloomberg Law Automation.
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.